Olfactomics Surgery SIGNED
BRINGING SURGERY TO THE 21ST CENTURY: REAL-TIME TISSUE ANALYSIS DURING CANCER SURGERY. Improving Patient Safety, Quality and Cost-Effectiveness
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Olfactomics Surgery project word cloud
Explore the words cloud of the Olfactomics Surgery project. It provides you a very rough idea of what is the project "Olfactomics Surgery" about.
Project "Olfactomics Surgery" data sheet
The following table provides information about the project.
| Coordinator |
OLFACTOMICS OY
Organization address contact info |
| Coordinator Country | Finland [FI] |
| Total cost | 2˙649˙375 € |
| EC max contribution | 1˙854˙562 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-04-01 to 2021-03-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | OLFACTOMICS OY | FI (TAMPERE) | coordinator | 1˙854˙562.00 |
Map
Project objective
Currently, cancer tumor removal operation is based on preoperative imaging and postoperative pathological examination. There is a strong global trend towards more tissue-sparing and minimally invasive surgery. If all cancer is not removed in the operation, a reoperation is needed, leading to additional costs, impaired cost-effectiveness and impaired quality of life of the patient. The rate of incomplete removal of a tumor ranges from 10-60%. The breakthrough innovative Olfactomics device allows the surgeon to analyze the operated tissue in real-time during cancer surgery leading to optimal tissue removal without compromising the workflow of the operation and facilitating the use of existing instrumentation. The solution is based on noninvasive, real-time analysis of surgical smoke. The reduced reoperation rate results in significant benefits for the patient, surgeon, hospital and society. The market potential is high. Easily reachable market for the breast cancer surgery is 850M€ and market for other applicable specialties (such as prostate cancer, skin cancer, and intestinal surgery) is over 2,000M€. Olfactomics Oy is a Finnish university-based spinoff company founded in 2015 to commercialize the results of over 10 years of clinical and technical research. The team consists of 13 specialists in surgery, medical technology, software, data analysis, financials and law. The team has excellent connections in the international healthcare industry and sensor technology industry. The technology is currently at TRL 7. The first commercial product for research use will be launched in 2019. This project will focus on scale-up to Olfactomics medical device on breast cancer surgery. The impacts by 2027 include: 3,000 Olfactomics devices sold; 300,000 Olfactomics breast cancer surgeries performed, 70,000 women saved from reoperation, 900M€ costs savings in health care, 100M€ revenue and 200 direct workplaces generated. Scale-up to several surgical areas will follow.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OLFACTOMICS SURGERY" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "OLFACTOMICS SURGERY" are provided by the European Opendata Portal: CORDIS opendata.